BYS10, a novel selective RET inhibitor, exhibits potent antitumor activity in preclinical models
Sign Up to like & getrecommendations! Published in 2025 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2025.1670140
Abstract: Background Aberrant alterations in the RET gene serve as oncogenic drivers in multiple cancers, making RET kinase inhibition a promising therapeutic strategy. However, acquired resistance limits the clinical efficacy of selective RET inhibitors. Methods Enzymatic… read more here.
Keywords: xenograft; ret; kif5b ret; bys10 ... See more keywords